Bridgewater Associates LP Sells 87,470 Shares of Certara, Inc. (NASDAQ:CERT)

Bridgewater Associates LP trimmed its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 52.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,816 shares of the company’s stock after selling 87,470 shares during the quarter. Bridgewater Associates LP’s holdings in Certara were worth $923,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CERT. The Manufacturers Life Insurance Company boosted its stake in shares of Certara by 4.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock valued at $317,000 after purchasing an additional 975 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Certara by 2.3% in the 2nd quarter. Louisiana State Employees Retirement System now owns 54,200 shares of the company’s stock valued at $751,000 after purchasing an additional 1,200 shares during the last quarter. Nicolet Advisory Services LLC boosted its stake in shares of Certara by 6.6% in the 3rd quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company’s stock valued at $273,000 after purchasing an additional 1,531 shares during the last quarter. KBC Group NV boosted its stake in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after purchasing an additional 1,584 shares during the last quarter. Finally, Blue Trust Inc. bought a new stake in shares of Certara in the 2nd quarter valued at $26,000. 73.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Barclays cut their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Friday, September 27th. Finally, Robert W. Baird cut their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Stock Performance

CERT opened at $11.21 on Monday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company’s fifty day moving average price is $10.81 and its two-hundred day moving average price is $12.98. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.87. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -56.05, a PEG ratio of 5.67 and a beta of 1.51.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s revenue was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.06 earnings per share. On average, analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Insider Activity

In related news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This represents a 9.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The trade was a 33.94 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by corporate insiders.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.